|SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness||NatureAugust 2020||
This pre-clinical study showed that an mRNA vaccine against COVID-19 induced potent neutralizing antibody responses and CD8 T cell responses and protected against SARS-CoV-2 infection in the lungs and nose of mice without evidence of vaccine-associated enhanced respiratory disease (VAERD) when given at sub-protective doses.
|Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates||New England Journal of MedicineJuly 2020||
This pre-clinical study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD).
|An mRNA Vaccine against SARS-CoV-2 — Preliminary Report||New England Journal of MedicineJuly 2020||
This Phase 1 interim analysis showed that an mRNA vaccine against COVID-19 induced rapid and strong immune responses against SARS-CoV-2, supporting further clinical development and the potential of mRNA as a vaccine platform.
|Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults||New England Journal of MedicineSEPTEMBER 2020||
Phase 1 clinical study of mRNA-1273 vaccine against SARS-Cov-2 showed a higher level of neutralizing antibodies with a 100-µg dose in healthy older adults with an acceptable safety profile.